$AGRX So many people here placing large bets on the "assumption" that this was delayed over a labeling issue. No one knows why it was extended. What we do know is that the FDA could not approve it yet. Will they, maybe, won't they, maybe. I would say that the odds of approval after the glowing adcom are good odds, but I also find the odds of not approving almost as good due to the content of the pre adcom letter from the FDA. I wouldn't buy this or short this. Too much risk either way.
  • 6
  • 6